Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia.

Khanna-Gupta A, Abayasekara N, Levine M, Sun H, Virgilio M, Nia N, Halene S, Sportoletti P, Jeong JY, Pandolfi PP, Berliner N.

J Biol Chem. 2012 Sep 21;287(39):32728-37. Epub 2012 Jul 31.

2.

Target proteins of C/EBPalphap30 in AML: C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9.

Geletu M, Balkhi MY, Peer Zada AA, Christopeit M, Pulikkan JA, Trivedi AK, Tenen DG, Behre G.

Blood. 2007 Nov 1;110(9):3301-9. Epub 2007 Aug 1.

3.

Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse.

Sportoletti P, Grisendi S, Majid SM, Cheng K, Clohessy JG, Viale A, Teruya-Feldstein J, Pandolfi PP.

Blood. 2008 Apr 1;111(7):3859-62. doi: 10.1182/blood-2007-06-098251. Epub 2008 Jan 22.

4.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G.

Blood. 2013 Jan 3;121(1):159-69. doi: 10.1182/blood-2012-05-428573. Epub 2012 Oct 25.

5.

Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes.

Ishikawa Y, Xu J, Sakashita G, Urano T, Suzuki T, Tomita A, Kiyoi H, Nakamura S, Naoe T.

Leuk Lymphoma. 2008 Dec;49(12):2359-64. doi: 10.1080/10428190802541815.

PMID:
19052985
6.

SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.

Inoue D, Kitaura J, Matsui H, Hou HA, Chou WC, Nagamachi A, Kawabata KC, Togami K, Nagase R, Horikawa S, Saika M, Micol JB, Hayashi Y, Harada Y, Harada H, Inaba T, Tien HF, Abdel-Wahab O, Kitamura T.

Leukemia. 2015 Apr;29(4):847-57. doi: 10.1038/leu.2014.301. Epub 2014 Oct 13.

7.

Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia.

Russ AC, Sander S, Lück SC, Lang KM, Bauer M, Rücker FG, Kestler HA, Schlenk RF, Döhner H, Holzmann K, Döhner K, Bullinger L.

Haematologica. 2011 Dec;96(12):1783-91. doi: 10.3324/haematol.2011.046888. Epub 2011 Aug 31.

8.

Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.

Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, Kondo T, Kuroiwa H, Okada M, Mori N, Motoji T.

Leuk Lymphoma. 2007 Nov;48(11):2141-4.

PMID:
17990177
9.

[THE CLINICAL SIGNIFICANCE OF GENETIC MUTATIONS IN ACUTE MYELOID LEUKEMIA].

Goryainova NV.

Lik Sprava. 2014 Dec;(12):10-8. Review. Ukrainian.

PMID:
26638462
10.

C/EBPα in normal and malignant myelopoiesis.

Friedman AD.

Int J Hematol. 2015 Apr;101(4):330-41. doi: 10.1007/s12185-015-1764-6. Epub 2015 Mar 10. Review.

11.

A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG)

Jaju RJ, Haas OA, Neat M, Harbott J, Saha V, Boultwood J, Brown JM, Pirc-Danoewinata H, Krings BW, Müller U, Morris SW, Wainscoat JS, Kearney L.

Blood. 1999 Jul 15;94(2):773-80.

12.

Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC.

Hirsch P, Tang R, Marzac C, Perrot JY, Fava F, Bernard C, Jeziorowska D, Marie JP, Legrand O.

Haematologica. 2012 Feb;97(2):241-5. doi: 10.3324/haematol.2010.034447. Epub 2011 Nov 4.

13.

The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.

Kuo YY, Hou HA, Chen YK, Li LY, Chen PH, Tseng MH, Huang CF, Lee FY, Liu MC, Liu CW, Chou WC, Liu CY, Tang JL, Yao M, Tien HF.

Haematologica. 2014 Dec;99(12):1799-807. doi: 10.3324/haematol.2014.107821. Epub 2014 Sep 5.

14.

Synergistic induction of galectin-1 by CCAAT/enhancer binding protein alpha and hypoxia-inducible factor 1alpha and its role in differentiation of acute myeloid leukemic cells.

Zhao XY, Zhao KW, Jiang Y, Zhao M, Chen GQ.

J Biol Chem. 2011 Oct 21;286(42):36808-19. doi: 10.1074/jbc.M111.247262. Epub 2011 Aug 31.

15.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 Feb 1;28(4):596-604. doi: 10.1200/JCO.2009.25.1496. Epub 2009 Dec 21.

16.

SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis.

Nian Q, Xiao Q, Wang L, Luo J, Chen LP, Yang ZS, Liu L.

Int J Mol Med. 2014 Apr;33(4):856-62. doi: 10.3892/ijmm.2014.1648. Epub 2014 Feb 7.

17.

CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.

Fuchs O, Provaznikova D, Kocova M, Kostecka A, Cvekova P, Neuwirtova R, Kobylka P, Cermak J, Brezinova J, Schwarz J, Markova J, Salaj P, Klamova H, Maaloufova J, Lemez P, Novakova L, Benesova K.

Blood Cells Mol Dis. 2008 May-Jun;40(3):401-5. doi: 10.1016/j.bcmd.2007.11.005. Epub 2008 Jan 8.

PMID:
18182175
18.

Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.

Babushok DV, Bessler M, Olson TS.

Leuk Lymphoma. 2016;57(3):520-36. doi: 10.3109/10428194.2015.1115041. Epub 2015 Dec 23.

19.

NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype.

Zhang Y, Zhang M, Yang L, Xiao Z.

Leuk Res. 2007 Jan;31(1):109-11. Epub 2006 May 5.

PMID:
16678898
20.

Role of nucleophosmin in embryonic development and tumorigenesis.

Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, Pandolfi PP.

Nature. 2005 Sep 1;437(7055):147-53. Epub 2005 Jul 6.

Supplemental Content

Support Center